



Attorney Docket No. P04864US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Connor, et al.

Group Art Unit:

1656

SERIAL NO:

09/780,762

Examiner:

Chunduru, S.

FILED:

February 9, 2001

Confirmation No: 6610

TITLE:

METHOD FOR AMPLIFYING FULL LENGTH SINGLE STRAND

POLYNUCLEOTIDE SEQUENCES

INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This information disclosure statement is being filed before the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. Copies of the listed references are enclosed. The Examiner is requested to consider the references and make them of record.

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement.

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

CERTIFICATE OF MAILING

I hereby certify that the above correspondence was mailed to the Assistant Commissioner for Patents, Washington, D.C. 20231, as First Class mail, postage prepaid, this

Authorization is hereby made to charge any additional fees required by this paper or credit any overpayment to Deposit Account 26-0084. A duplicate of this paper is attached.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitt

Heidi S. Nebel

Reg. No. 37,719

ZARLEY, McKEE, THOMTE, VOORHEES

& SEASE

801 Grand Avenue, Suite 3200

Des Moines, Iowa 50309-2721

Phone No. (515) 288-3667

Fax No. (515) 288-1338

CUSTOMER NO: 27407

- msw -

Attorneys of Record

Substitute for form 1449A/PTO

AUG 0 8 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
Sheet of

	AUG H CEI	
Application Number	09/780,762	= 1
Filing Date	February 9., 2001	ER 0
First Named Inventor	James R. Connor	16
Group Art Unit	1656	000
Examiner Name	Chunduru, S.	2/0
Attorney Docket Number	P046864US2	90
		(3)

	U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No.1	U.S. Patent Document Kind Code ² NUMBER if known)		U.S. Patent Document Name of Patentee or Applicant Dat Kind Code of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
8PC	1	4,994,370		Silver, Jonathan, et al.	02/19/1991	
				• W		
						· · · · · · · · · · · · · · · · · · ·
						· · · · · · · · · · · · · · · · · · ·
		ļ				
						·····

	FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No.1	Office	Foreign Patent Doc Number 4	ument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
SPL.	2	PC	WO 92/01813		SYNGENE, INC.	02/06/1992		
	3	PC	WO 94/03624		AUEBACH, JEFFREY I	02/17/1994		
	4	PC1	WO 96/38591		INCYTE PHARMACEUTICALS, INC.	12/05/1996		
V	5	PCT	WO 97/19193		YALE UNIVERSITY	05/29/1997		
	-							

	The second of th	The second secon		
Examiner	Realistic Characterists	Date		പ
Signature	Brasna Chemanni	Considered	11/201	<u> </u>

^{*}EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
Sheet 2 of

	Complete if Known	NI NI
Application Number	09/780,762	Ä
Filing Date	February 9., 2001	16
First Named Inventor	James R. Connor	8
Group Art Unit	1656	1/2
Examiner Name	Chunduru, S.	9
Attorney Docket Number	P04684US2	- 0

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
spe-	6	CHEN G ET AL.: "GENERATION OF EPITOPE-TAGGED PROTEINS BY INVERSE PCR MUTAGENESIS" <u>BIOTECHNIQUES</u> , EATON PUBLISHING NATICK, US, 26(5) 814-816 (05/1999)	
	7	YE ZHENG ET AL: "cDNA cloning by amplification of circularized first strand cDNAs reveals non-IRE-regulated iron-responsive mRNAs." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 275(1) 223-227 (08/2000)	
	8	Z. YE AND R.J. CONNERS: "CLONING FULL LENGTH CDNA BY AMPLIFICATION OF FIRST STRAND CDNA WITH SPECIFIC PRIMERS" FASEB JOURNAL, 14(8) a1473 (05/2000) FASEB, BATHESDA, MD, US Am. Soc. for Biochem. And Mol. Biol., Joint Meeting with French Pharm. Soc., of Canada, Boston, MA, 4-8. June 2000; Abstract No. 928 presented Tuesday Morning June 6, 2000; abstract	
	9	"USING MISMATCHED PRIMER-TEMPLATE PAIRS IN TOUCHDOWN PCR" <u>BIOTECHNIQUES</u> , US, ETON PUBLISHING, NATICK, 16(5) 812-814 (1994)	
J	10	TOWNER P ET AL: "CDNA CLONING OF 5' TERMINAL REGIONS" <u>NUCLEIC ACIDS RESEARCH</u> , 20(17) 4669-4670 (1992)	
77			
3			
		A	
			-
			<u> </u>